Coherus Oncology (CHRS) Gains from Investment Securities (2012 - 2026)

Coherus Oncology has disclosed Gains from Investment Securities across 15 years of filings, most recently posting $72078.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $72078.0, down 70.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $72078.0 (up 104.45% YoY), and the FY2025 annual result was $5.7 million, down 80.22% from the prior year.
• Gains from Investment Securities came in at $72078.0 for Q1 2026 at Coherus Oncology, up from -$47000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $2.8 million in Q1 2023 to a low of -$2.6 million in Q4 2024.
• The 5-year median for Gains from Investment Securities is $58771.0 (2022), against an average of -$40163.1.
• Across the five-year window, Gains from Investment Securities tumbled 10682.61% in 2022 and jumped 1398.03% in 2023, its largest moves.
• Coherus Oncology's Gains from Investment Securities stood at -$2.4 million in 2022, then soared by 88.82% to -$272000.0 in 2023, then tumbled by 847.06% to -$2.6 million in 2024, then jumped by 98.18% to -$47000.0 in 2025, then soared by 253.36% to $72078.0 in 2026.
• The last three Gains from Investment Securities figures came in at $72078.0 (Q1 2026), -$47000.0 (Q4 2025), and $3415.0 (Q3 2025), per Business Quant data.